ArticleBlood vessels, thrombosis & hemostasis2026
Impact of ABO blood groups on residual pulmonary vascular obstruction in patients with unprovoked pulmonary embolism.
Article in Blood vessels, thrombosis & hemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00740883 (Eighteen Months of Oral Anticoagulant Therapy Versus Placebo After 6 Six Months of Anticoagulation for a First Episode of Idiopathic Pulmonary Embolism), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Eighteen Months of Oral Anticoagulant Therapy Versus Placebo After 6 Six Months of Anticoagulation for a First Episode of Idiopathic Pulmonary Embolism: a Multicentre Double-blind Randomized Controlled Trial. "PADIS-PE" Study.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After completing anticoagulant therapy for acute pulmonary embolism (PE), patients may have persistent thrombotic materials in the lung, causing residual pulmonary vascular obstruction (RPVO). Detectable by imaging, RPVO is associated with an increased risk of recurrent events and chronic complications. Little is known about RPVO risk factors including genetics. ABO is known to be associated with RPVO-related traits, such as recurrent PE and chronic thromboembolic pulmonary hypertension. This study specifically investigated the association between genetically determined ABO blood groups and RPVO in patients with unprovoked PE. This work relies on 2 French cohorts and 1 Canadian cohort, totaling 586 patients with unprovoked PE and with RPVO measurements. In each study, 5 ABO polymorphisms were used to infer ABO blood groups: rs8176719-delG, rs41302905-T, rs2519093-T, rs1053878-A, and rs8176743-T alleles tagging for O1, O2, A1, A2, and B, respectively. Associations between ABO blood groups and RPVO were assessed in each study using a compound Poisson-gamma model, which accounts for the semicontinuous RPVO distribution. Study-specific results were then combined through meta-analysis. A simulation study confirmed sufficient power (>80%) to detect moderate genetic effects (1.3-fold increased risk for common variants with allele frequency ≥0.05). Despite this, no significant association was observed between ABO blood groups and RPVO. ABO blood groups are unlikely to be major risk factors for RPVO. Nevertheless, this study provides an important foundation for future large-scale genetic investigations aimed at identifying the molecular determinants of RPVO. This study was registered at www.clinicaltrials.gov as NCT00740883.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.